Josh Ofman, MD, MSHS, is President at GRAIL. Josh serves as Chairman of the Board of Directors of EveryONE Medicines, a company dedicated to precision medicine for rare genetic diseases, and serves on the Board of the Precision Medicine Coalition. He has previously served on the Board of Directors of Cell BT, Inc, an immuno-therapy company.
Previously, Josh spent more than 15 years at Amgen, his last role being Senior Vice President, Global Value, Access and Policy. Prior to that, Josh was a faculty member in the Department of Medicine and Health Services Research at University of California, Los Angeles (UCLA) School of Medicine, Division of Digestive Diseases at Cedars-Sinai Medical Center, as well as Senior Vice President of Zynx Health Inc., a subsidiary of Cerner Corp. Josh holds a BA in history and philosophy of science from the University of California, Berkeley, and an MD from the University of California, Irvine, School of Medicine. Josh completed his medical training at the UCLA School of Medicine divisions of Internal Medicine and Digestive Diseases, where he also completed the NRSA Primary Care Research Fellowship in collaboration with the RWJ Clinical Scholars Program. Josh also received a Masters of Science in Health Services Research (MSHS) from the UCLA School of Public Health.
What is Joshua J. Ofman's net worth?
The estimated net worth of Joshua J. Ofman is at least $41.57 million as of October 15th, 2026. Dr. Ofman owns 342,271 shares of GRAIL stock worth more than $41,565,390 as of November 8th. This net worth evaluation does not reflect any other assets that Dr. Ofman may own. Learn More about Joshua J. Ofman's net worth.
How do I contact Joshua J. Ofman?
Has Joshua J. Ofman been buying or selling shares of GRAIL?
Within the last three months, Joshua J. Ofman has sold $2,737,000.00 of GRAIL stock. Most recently, Joshua J. Ofman sold 20,000 shares of the business's stock in a transaction on Thursday, October 15th. The shares were sold at an average price of $136.85, for a transaction totalling $2,737,000.00. Following the completion of the sale, the chief executive officer now directly owns 342,271 shares of the company's stock, valued at $46,839,786.35. Learn More on Joshua J. Ofman's trading history.
Who are GRAIL's active insiders?
Are insiders buying or selling shares of GRAIL?
During the last year, insiders at the sold shares 20 times. They sold a total of 441,702 shares worth more than $30,409,271.56. The most recent insider tranaction occured on October, 15th when CEO
Joshua J. Ofman sold 20,000 shares worth more than $2,737,000.00. Insiders at GRAIL own 1.8% of the company.
Learn More about insider trades at GRAIL. Information on this page was last updated on 10/15/2026.
